Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Abionyx Pharma S.A.. (8/27/19). "Press Release: Change of Name and Stock Symbol/Mnemonic of Abionyx Pharma Shares (formerly Cerenis Therapeutics) as of August 29, 2019". Toulouse & Lakeland, US.

Organisations Organisation Abionyx Pharma S.A. (Euronext Paris: ABNX)
  Group Abionyx (Group)
  Organisation 2 Cerenis Therapeutics S.A.
  Today Abionyx Pharma S.A. (Euronext Paris: ABNX)
  Group Abionyx (Group)
Products Product drug development
  Product 2 drug delivery technology (drug formulation technology)
Index term Index term Cerenis–NewCap: public relations, 201503 service existent by NewCap.
Persons Person Delouvrier, Louis-Victor (NewCap 201809)
  Person 2 Merigeau, Nicolas (NewCap 201502)

Following the Extraordinary General Meeting of 21 June 2019, the shareholders of CERENIS Therapeutics approved the proposal for a new company name, which is now ABIONYX Pharma.

Beginning on 29 August 2019, the name, ISIN code and symbol/mnemonic of the share listed on Euronext Paris will be as follows:

- Share name: ABIONYX Pharma (replacing CERENIS Therapeutics)
- ISIN code of the share: FR0012616852 (unchanged)
- Stock symbol / Mnemonic code of the action: ABNX (replacing CEREN).

ABIONYX Pharma is a new generation biotech company that seeks to leverage a rich portfolio of clinical and preclinical programs inherited from the assets of CERENIS Therapeutics, to focus on the discovery and development of innovative therapies.

About ABIONYX Pharma:

ABIONYX Pharma is a new biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy, as well as molecules targeted for other indications.


NewCap Investor relations
Louis-Victor Delouvrier
+33 (0)1 44 71 98 53

NewCap Media relations
Nicolas Merigeau
+33 (0)1 44 71 94 9

Record changed: 2019-09-11


Picture [iito] Plain Stupid Simple 650x80px

More documents for Abionyx (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top